Kerry A. Rogers - Concepedia

Author

Kerry A. Rogers

Also Known As

Daniel Jones, K A Rogers, K. Rogers, K.A. Rogers, Kerry A Rogers, Kerry A. Rogers, Kerry Anne Rogers, Kerry Rogers, Leonid L Yavorkovsky, Rogers, K.

278

Publications

4.9K

Citations

H-Index

Concepts

All Affiliations

The Ohio State University The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute The University of Texas MD Anderson Cancer Center Dana-Farber Cancer Institute The Ohio State University Wexner Medical Center

About

Kerry A. Rogers is an author at The Ohio State University specializing in medicine, immunology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	14	1.1K
2	Health Sciences	3	3	132
3	Public Health	1	1	158
4	Social Sciences	1	1	17
5	Cell Biology	1	1	12

Kerry A. Rogers

Publications

Citations

H-Index

Page 1

	Year	Citations
Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL Jennifer A. Woyach, Amy S. Ruppert, Nyla A. Heerema, New England Journal of Medicine	2018	927
<i>BTK</i><sup>C481S</sup>-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia Jennifer A. Woyach, Amy S. Ruppert, Daphne Guinn, Journal of Clinical Oncology Hematological MalignancyChronic Lymphocytic LeukemiaBruton Tyrosine KinaseMedicineMixed-phenotype Acute Leukemia	2017	461
Hypertension and incident cardiovascular events following ibrutinib initiation Tyler Dickerson, Tracy Wiczer, Allyson Waller, Blood	2019	237
The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation Sean D. Reiff, Rose Mantel, Lisa L. Smith, Cancer Discovery	2018	161
Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib Tracy Wiczer, Lauren Levine, Jessica Brumbaugh, Blood Advances Heart FailurePharmacotherapyAcute Myocardial InfarctionThrombosisCumulative Incidence	2017	158
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia Kerry A. Rogers, Ying Huang, Amy S. Ruppert, Blood	2018	107
Resistance to Acalabrutinib in CLL Is Mediated Primarily By BTK Mutations Jennifer A. Woyach, Ying Huang, Kerry A. Rogers, Blood	2019	104
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia Kerry A. Rogers, Philip A. Thompson, John N. Allan, Haematologica ImmunologyPathologyPhase Ii StudyPharmacotherapyImmunotherapy	2021	102
Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia Kerry A. Rogers, Ying Huang, Amy S. Ruppert, Journal of Clinical Oncology	2020	101
Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia Kerry A. Rogers, A. S. Ruppert, Anissa Bingman, Leukemia Hematological MalignancyLymphoid NeoplasiaAutoimmune CytopeniasAutoimmune DiseaseChronic Lymphocytic Leukemia	2015	94

Page 1